This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meier, J. J. Articles by Nauck, M. A. Search for Related Content PubMed PubMed Citation Articles by Meier, J. J. Articles by Nauck, M. A.

Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes

Department of Medicine I, St. Josef Hospital, Ruhr University (J.J.M., B.G., S.S., O.G., W.E.S., M.A.N.), 44791 Bochum, Germany; Department of Medical Physiology, The Panum Institute, University of Copenhagen (J.J.H.), 2200 Copenhagen, Denmark; and Diabeteszentrum (M.A.N.), 37431 Bad Lauterberg, Germany

Address all correspondence and requests for reprints to: Dr. Juris J. Meier, Medizinische Klinik I, St. Josef Hospital, Klinikum der Ruhr Universität Bochum, Gudrunstrasse 56, 44791 Bochum, Germany. E-mail: Juris.Meier{at}ruhr-uni-bochum.de.

The effects of different iv doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with type 2 diabetes received three different infusion rates of GLP-1 (0.4, 0.8, and 1.2 pmol/kg·min) or placebo in the fasting state and after a solid test meal (containing [¹³C]octanoic acid). Blood was drawn for glucose, insulin, C-peptide, glucagon, and GLP-1 determinations. The gastric emptying rate was calculated from the ¹³CO₂ excretion rates in breath samples. Statistics were determined using repeated measures ANOVA and Duncan’s post hoc test.

Plasma glucose concentrations were equally normalized with all GLP-1 doses (P < 0.001). Insulin and C-peptide concentrations dose-dependently rose during GLP-1 infusion in the fasting state (P < 0.05), but were dose-dependently reduced by GLP-1 after meal ingestion (P = 0.0031 and 0.0074, respectively). Glucagon secretion was suppressed with GLP-1. Gastric emptying was decelerated by GLP-1 in a dose-dependent fashion (P < 0.001).

Despite a dose-dependent stimulation of insulin secretion, glucose normalization can be achieved even with 0.4 pmol GLP-1/kg·min. Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes.

This work was supported by Deutsche Forschungsgemeinschaft (Na 203/6-1) and FoRUM (F348/2002).

Abbreviations: GLP-1, Glucagon-like peptide 1; PDR, percentage dose of ¹³C recovered.

This article has been cited by other articles:

				C. W. Chia, O. D. Carlson, W. Kim, Y.-K. Shin, C. P. Charles, H. S. Kim, D. L. Melvin, and J. M. Egan Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes Diabetes, June 1, 2009; 58(6): 1342 - 1349. [Abstract] [Full Text] [PDF]

				L. M. Lauffer, R. Iakoubov, and P. L. Brubaker GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell Diabetes, May 1, 2009; 58(5): 1058 - 1066. [Abstract] [Full Text] [PDF]

				K. Vollmer, H. Gardiwal, B. A. Menge, O. Goetze, C. F. Deacon, W. E. Schmidt, J. J. Holst, and J. J. Meier Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1379 - 1385. [Abstract] [Full Text] [PDF]

				M. J. Riedel, C. W. K. Lee, and T. J. Kieffer Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E936 - E944. [Abstract] [Full Text] [PDF]

				J. Hlebowicz, A. Hlebowicz, S. Lindstedt, O. Bjorgell, P. Hoglund, J. J Holst, G. Darwiche, and L.-O. Almer Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects Am. J. Clinical Nutrition, March 1, 2009; 89(3): 815 - 821. [Abstract] [Full Text] [PDF]

				W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]

				M. A Nauck Liraglutide, a once-daily human GLP-1 analogue The British Journal of Diabetes & Vascular Disease, November 1, 2008; 8(2_suppl): S26 - S33. [Abstract] [PDF]

				C. W. Chia and J. M. Egan Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3703 - 3716. [Abstract] [Full Text] [PDF]

				M. Ellrichmann, M. Kapelle, P. R. Ritter, J. J. Holst, K.-H. Herzig, W. E. Schmidt, F. Schmitz, and J. J. Meier Orlistat Inhibition of Intestinal Lipase Acutely Increases Appetite and Attenuates Postprandial Glucagon-Like Peptide-1-(7-36)-Amide-1, Cholecystokinin, and Peptide YY Concentrations J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3995 - 3998. [Abstract] [Full Text] [PDF]

				A. E. Bharucha, N. Charkoudian, C. N. Andrews, M. Camilleri, D. Sletten, A. R. Zinsmeister, and P. A. Low Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R874 - R880. [Abstract] [Full Text] [PDF]

				K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance Diabetes, March 1, 2008; 57(3): 678 - 687. [Abstract] [Full Text] [PDF]

				A. El-Ouaghlidi, E. Rehring, J. J. Holst, A. Schweizer, J. Foley, D. Holmes, and M. A. Nauck The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				A. Basu, N. Charkoudian, W. Schrage, R. A. Rizza, R. Basu, and M. J. Joyner Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1289 - E1295. [Abstract] [Full Text] [PDF]

				K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1085 - E1091. [Abstract] [Full Text] [PDF]

				J. J. Meier, J. J. Holst, W. E. Schmidt, and M. A. Nauck Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E849 - E856. [Abstract] [Full Text] [PDF]

				A. Vella, G. Bock, P. D. Giesler, D. B. Burton, D. B. Serra, M. L. Saylan, B. E. Dunning, J. E. Foley, R. A. Rizza, and M. Camilleri Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes Diabetes, May 1, 2007; 56(5): 1475 - 1480. [Abstract] [Full Text] [PDF]

				T. J. Little, S. Doran, J. H. Meyer, A. J. P. M. Smout, D. G. O'Donovan, K.-L. Wu, K. L. Jones, J. Wishart, C. K. Rayner, M. Horowitz, et al. The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E647 - E655. [Abstract] [Full Text] [PDF]

				J. J. Meier, A. Gethmann, M. A. Nauck, O. Gotze, F. Schmitz, C. F. Deacon, B. Gallwitz, W. E. Schmidt, and J. J. Holst The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1118 - E1123. [Abstract] [Full Text] [PDF]

				T. J. Little, A. N. Pilichiewicz, A. Russo, L. Phillips, K. L. Jones, M. A. Nauck, J. Wishart, M. Horowitz, and C. Feinle-Bisset Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1916 - 1923. [Abstract] [Full Text] [PDF]

				G. M. Bray Exenatide Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 411 - 418. [Abstract] [Full Text] [PDF]

				J. J. Meier, G. Kemmeries, J. J. Holst, and M. A. Nauck Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects Diabetes, July 1, 2005; 54(7): 2212 - 2218. [Abstract] [Full Text] [PDF]

				P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF]

				G Uckaya, P Delagrange, A Chavanieu, G Grassy, M-F Berthault, A Ktorza, E Cerasi, G Leibowitz, and N Kaiser Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue J. Endocrinol., March 1, 2005; 184(3): 505 - 513. [Abstract] [Full Text] [PDF]

				M. A. Nauck, B. Baller, and J. J. Meier Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S190 - S196. [Abstract] [Full Text] [PDF]

				J. J. Meier, B. Gallwitz, B. Kask, C. F. Deacon, J. J. Holst, W. E. Schmidt, and M. A. Nauck Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects Diabetes, December 1, 2004; 53(suppl_3): S220 - S224. [Abstract] [Full Text] [PDF]

				J. J. Meier, O. Goetze, J. Anstipp, D. Hagemann, J. J. Holst, W. E. Schmidt, B. Gallwitz, and M. A. Nauck Gastric inhibitory polypeptide does not inhibit gastric emptying in humans Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E621 - E625. [Abstract] [Full Text] [PDF]